Open Access
ARTICLE
TIMP-3 Increases the Chemosensitivity of Laryngeal Carcinoma to Cisplatin via Facilitating Mitochondria-Dependent Apoptosis
Xiaohui Shen, Xia Gao, Hui Li, Yajun Gu, Junguo Wang
Department of Otolaryngology Head and Neck, Nanjing Drum Tower Hospital Affiliated to Nanjing University Medical School,
Nanjing, P.R. China
Oncology Research 2019, 27(1), 73-80. https://doi.org/10.3727/096504018X15201099883047
Abstract
Laryngeal carcinoma is a type of head and neck carcinoma with a high incidence and mortality. Chemotherapy
treatments of human laryngeal carcinoma may fail due to the development of chemoresistance. Tissue inhibitor
of metalloproteinase 3 (TIMP-3) has been shown to be implicated in a number of pathological processes typical
for cancer. The present study aims to investigate the involvement of TIMP-3 in the chemoresistance of laryngeal
carcinoma. We showed that TIMP-3 expression was significantly decreased in chemoresistant laryngeal carcinoma tissues compared with chemosensitivity tissues. Patients with low TIMP-3 expression exhibited poorer
overall survival than those with high TIMP-3 expression. Moreover, cisplatin-resistant Hep-2 cells (Hep-2/R)
were associated with the inhibition of mitochondrial membrane potential (MtMP) depolarization after cisplatin
challenge. In addition, cisplatin resulted in a more pronounced mitochondrial cytochrome c release into the
cytoplasm in Hep-2 cells than in their resistant variants. Overexpression of TIMP-3 by an adenovirus encoding
TIMP-3 cDNA remarkably enhanced cisplatin-induced apoptosis, cytochrome c release, and caspase activation
in Hep-2/R cells, thereby sensitizing cancer cells to cisplatin. On the other hand, downregulation of TIMP-3
markedly inhibited cisplatin-induced apoptosis in Hep-2 cells through attenuating mitochondria-dependent
pathway activation. Taken together, these results demonstrate that decreased TIMP-3 expression may contribute to cisplatin resistance via inhibition of mitochondria-dependent apoptosis, indicating that forced TIMP-3
expression may be a useful strategy to improve the efficacy of cisplatin to treat laryngeal carcinoma.
Keywords
Cite This Article
Shen, X., Gao, X., Li, H., Gu, Y., Wang, J. (2019). TIMP-3 Increases the Chemosensitivity of Laryngeal Carcinoma to Cisplatin via Facilitating Mitochondria-Dependent Apoptosis.
Oncology Research, 27(1), 73–80.